PCN89 - COST –EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2 + BREAST CANCER IN REPUBLIC OF MACEDONIA
| Autor: | Kapedanovska Nestorovska, A., Sterjev, Z., Naumovska, Z., Dimovski, A., Grozdanova, A., Suturkova, L. |
|---|---|
| Zdroj: | In Value in Health October 2018 21 Supplement 3:S29-S29 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect